Varker Tracey, Watson Loretta, Gibson Kari, Forbes David, O'Donnell Meaghan L
Phoenix Australia- Centre for Posttraumatic Mental Health, Department of Psychiatry, University of Melbourne, Melbourne, Australia.
J Psychoactive Drugs. 2021 Jan-Mar;53(1):85-95. doi: 10.1080/02791072.2020.1817639. Epub 2020 Sep 15.
The aim of this systematic review was to examine the efficacy of MDMA, ketamine, LSD, and psilocybin for the treatment of posttraumatic stress disorder (PTSD). A search of four databases for English language, peer-reviewed literature published from inception to 18th October 2019 yielded 2,959 records, 34 of which were screened on full-text. Observational studies and RCTs which tested the efficacy of MDMA, ketamine, LSD, or psilocybin for reducing PTSD symptoms in adults, and reported changes to PTSD diagnosis or symptomatology, were included. Nine trials (five ketamine and four MDMA) met inclusion criteria. Trials were rated on a quality and bias checklist and GRADE was used to rank the evidence. The evidence for ketamine as a stand-alone treatment for comorbid PTSD and depression was ranked "very low", and the evidence for ketamine in combination with psychotherapy as a PTSD treatment was ranked "low". The evidence for MDMA in combination with psychotherapy as a PTSD treatment was ranked "moderate".
本系统评价的目的是研究摇头丸、氯胺酮、麦角酸二乙酰胺（LSD）和裸盖菇素治疗创伤后应激障碍（PTSD）的疗效。检索四个数据库，查找从创刊至2019年10月18日发表的英文、同行评审文献，共获得2959条记录，其中34条进行了全文筛选。纳入了测试摇头丸、氯胺酮、LSD或裸盖菇素减轻成人PTSD症状疗效，并报告PTSD诊断或症状变化的观察性研究和随机对照试验（RCT）。九项试验（五项氯胺酮试验和四项摇头丸试验）符合纳入标准。根据质量和偏倚清单对试验进行评分，并使用GRADE对证据进行分级。氯胺酮作为PTSD合并抑郁症单独治疗的证据等级为“极低”，氯胺酮联合心理治疗作为PTSD治疗的证据等级为“低”。摇头丸联合心理治疗作为PTSD治疗的证据等级为“中等”。
